US2015315157A1PendingUtilityA1

Prolyl hydroxylase inhibitors

60
Assignee: GLAXOSMITHKLINE LLCPriority: Jun 23, 2006Filed: Jul 2, 2015Published: Nov 5, 2015
Est. expiryJun 23, 2026(expired)· nominal 20-yr term from priority
Inventors:Duke M. FitchAntony N. ShawKenneth Wiggall
A61P 9/10A61P 7/00A61P 43/00A61P 9/00A61P 7/06C07D 401/04C07D 405/10C07D 409/04C07D 409/10C07D 239/22C07D 417/10C07D 413/06A61K 31/515C07D 405/04C07D 239/62C07D 239/60C07D 413/10C07D 239/54A61K 31/47A61K 31/495C07D 487/08
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . The compound: 
       
         
           
           
               
               
           
         
       
       or a salt thereof. 
     
     
         2 . The compound: 
       
         
           
           
               
               
           
         
       
       or a salt thereof. 
     
     
         3 . The compound: 
       
         
           
           
               
               
           
         
       
       or a salt thereof. 
     
     
         4 . A pharmaceutical composition for oral administration which comprises 1-700 mg of a compound as described in  claim 1  and one or more pharmaceutically acceptable excipient. 
     
     
         5 . A pharmaceutical composition for oral administration which comprises 1-700 mg of a compound as described in  claim 2  and one or more pharmaceutically acceptable excipient. 
     
     
         6 . A pharmaceutical composition for oral administration which comprises 1-700 mg a compound as described in  claim 3  and one or more pharmaceutically acceptable excipient. 
     
     
         7 . A method of treating ischemia in a human, said method comprising administering a pharmaceutical composition according to  claim 4 . 
     
     
         8 . A method of treating ischemia in a human, said method comprising administering a pharmaceutical composition according to  claim 5 . 
     
     
         9 . A method of treating ischemia in a human, said method comprising administering a pharmaceutical composition according to  claim 6 .

Join the waitlist — get patent alerts

Track US2015315157A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.